Table 2.

Final predictive probabilities of success of ganitumab and metformin with paclitaxel followed by anthracyclines in HER2− biomarker signatures. The combination failed to graduate in any of the three signatures.

Biomarker signature	Estimated rate of pathologic complete response % (95% Probability Interval)		Prob. superior to control, %	Predictive prob. of success in phase III Trial, %
	Ganitumab n = 106	Control n = 128
All HER2−	22 (13–31)	16 (10–23)	89	33
HR+/HER2−	14 (4–24)	12 (4–19)	61	21
HR−/HER2−	32 (17–46)	21 (11–32)	91	51